Form D · Biotechnology
Mammoth Biosciences, Inc.
San Francisco, CA · CIK 0001750963
Offering snapshot reported Aug 23, 2018 · SEC filing
- Reported sold
- $13.2M Offering amount: $13.2M
- Investors reported
- 28 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 15, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 23, 2018 | Initial | $13,156,347 | No comparison | 28 | SEC filing |
| Aug 23, 2018 | Initial | $7,410,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-319929
Source: Form D, filed Aug 23, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Janice Chen | Executive |
| Lucas Harrington | Executive |
| Trevor Martin | Director, Executive |
| Urshit Parikh | Director |
| Ashley Tehranchi | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
953 Indiana Street
San Francisco, CA, 94107
San Francisco, CA, 94107